CLINIMIX E 2.75/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER

Clinical safety rating: caution

Comprehensive clinical and safety monograph for CLINIMIX E 2.75/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER (CLINIMIX E 2.75/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER).

How it works

CLINIMIX E 2.75/10 is a parenteral nutrition solution providing amino acids, dextrose, electrolytes, and calcium. Amino acids serve as substrates for protein synthesis, dextrose provides caloric energy, and electrolytes maintain fluid and electrolyte balance.

What the body does with it

Metabolism	Amino acids are metabolized via transamination, deamination, and the urea cycle; dextrose is metabolized via glycolysis and the Krebs cycle; electrolytes are handled by renal and gastrointestinal mechanisms.
Excretion	Renal excretion of infused amino acids and electrolytes; glucose is metabolized to CO2 and water; 100% of water and electrolytes excreted renally.
Half-life	Not applicable as a fixed combination product; individual components have half-lives: amino acids ~0.5-2 h, dextrose ~2-4 h, electrolytes vary (e.g., calcium ~2-4 h).
Protein binding	Amino acids: minimal (<20% bound); calcium: ~45% bound to albumin; dextrose: negligible.
Volume of Distribution	Amino acids: 0.5-1 L/kg (total body water); calcium: 0.6 L/kg; dextrose: 0.2-0.4 L/kg.
Bioavailability	100% intravenous bioavailability.
Onset of Action	Immediate upon IV infusion; metabolic effects begin within minutes.
Duration of Action	Duration of nutritional support equals infusion duration; metabolic effects persist for 1-4 h post-infusion depending on component.

Classification & Brands

Dosing & administration

Intravenous infusion. Adult dose: 1-2 L per day, administered at a rate not exceeding 100 mL/hour initially, then adjusted based on metabolic and fluid requirements. Each liter contains amino acids 27.5 g, dextrose 100 g, and electrolytes including calcium.

Dosage form	INJECTABLE
Renal impairment	For GFR < 30 mL/min: use with caution, reduce protein load to 0.6-0.8 g/kg/day; monitor phosphate and potassium levels closely. For GFR 30-60 mL/min: standard dosing but monitor electrolytes. For GFR >60 mL/min: no adjustment needed.
Liver impairment	For Child-Pugh class B or C: reduce amino acid content to 0.5-0.7 g/kg/day; avoid use in hepatic encephalopathy. For Child-Pugh A: standard dosing with monitoring of ammonia levels.
Pediatric use	Weight-based dosing: initial infusion rate 0.1-0.15 mL/kg/hour, increase gradually to target 0.3-0.5 mL/kg/hour; maintain total fluid intake 100-150 mL/kg/day. Adjust based on glucose tolerance and electrolyte balance.
Geriatric use	Elderly patients: start at lower end of dosing range (e.g., 500 mL to 1 L per day) and titrate slowly; monitor for fluid overload, hyperglycemia, and electrolyte imbalances due to reduced renal and cardiac reserve.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Breastfeeding	Considered compatible with breastfeeding. M/P ratio not determined; however, components are endogenous nutrients that are normally present in breast milk. Intravenous infusion results in maternal plasma levels similar to postprandial states, and no adverse effects on nursing infants are anticipated.
Teratogenic Risk	No known teratogenic risk; amino acids, dextrose, and electrolytes are essential nutrients. Inadequate nutrition may pose risks, but the formulation itself is not associated with teratogenicity. Standard precautions apply for intravenous therapy during pregnancy.

Warnings & precautions

■ FDA Black Box Warning

None.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Hypersensitivity to any component","Severe metabolic acidosis","Hyperglycemia uncontrolled by insulin","Severe electrolyte or fluid imbalances","Anuria or oliguria","Uncontrolled seizure disorders","Hepatic coma"]

Clinical Precautions

Precautions	["Risk of infections due to central line use","Metabolic complications including hyperglycemia, acidosis, and electrolyte imbalances","Hepatic steatosis and cholestasis","Osteoporosis and bone demineralization","Withdrawal symptoms if discontinued abruptly"]
Food/Dietary	No direct food interactions as this is an intravenous solution. However, oral dietary intake should be coordinated with TPN to avoid overfeeding or electrolyte imbalances. Avoid concurrent administration of oral calcium or phosphate supplements without medical guidance due to potential precipitation risk in the IV line. Monitor total nutrient intake from all sources.

Clinical Tips & Counseling

Drug interactions

Loading safety data…